Business Wire

IARPA Funds Team Involving DNA Script, the Broad Institute, and Harvard University for DNA Data Storage Research and Development

15.1.2020 20:10:00 EET | Business Wire | Press release

Share

DNA Script today announced that the company and its Molecular Encoding Consortium partners have been awarded a multi-phase contract worth up to

$23 million from the Intelligence Advanced Research Projects Activity’s (IARPA) Molecular Information Storage (MIST) program. The goal of the project is to develop sequence-controlled polymers as the basis for deployable storage technologies that can eventually scale into the exabyte regime and beyond with reduced physical footprint, power and cost requirements relative to conventional storage technologies.

The Molecular Encoding Consortium is led by the Laboratory of Dr. Robert Nicol at the Broad Institute of MIT and Harvard and includes DNA Script and Professor Donhee Ham’s Research Group at Harvard University. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument over the 4-year duration of the program. The consortium plans to collaborate with Illumina to leverage its sequencing-by-synthesis (SBS) technologies for accurate, low cost decoding.

Massive amounts of digital data are generated every day, and emerging technologies such as autonomous cars and artificial intelligence will further increase the need for data storage at unprecedented scales. This causes major challenges to private and public organizations, which currently rely on exabyte-scale data centers that have large footprints, consume megawatts of power and cost hundreds of millions of dollars to build, operate and maintain over their lifetimes. It is expected that the anticipated growth in data storage requirements cannot be addressed by current resource-intensive technologies. Nucleic acid-based systems hold promise to store this information with radically reduced physical footprints, power and cost requirements.

This technology is not mature yet and will require extensive development to be ready to use. IARPA has therefore launched the MIST program to fund initiatives that could turn molecular-based data storage into reality. The Molecular Encoding Consortium is one of these funded projects.

“This contract with IARPA, which is part of the Office of the Director of National Intelligence, in partnership with prestigious partners such as the Broad Institute and Harvard University is a strong recognition of DNA Script’s results and leadership in developing enzymatic template-free nucleic acid synthesis,” said Dr. Thomas Ybert, CEO of DNA Script. “However, it is only the beginning of this ambitious project, which will require us to push current technological limits to bring to life our cutting-edge technology while also delivering an operational solution to one of the most important challenges of our time.”

“This project at the intersection of molecular biology, physics, chemistry, information theory and electrical engineering leverages the multi-disciplinary capabilities of our laboratory, our exceptional consortium partners and the collaborative nature of our Institute,” said Dr. Robert Nicol, Senior Director of Technology Development at the Broad Institute and the consortium’s Principal Investigator. “The objectives set out by IARPA for this four-year program are ambitious and will require scientific innovations, as well as robust and scalable technologies.”

“The Molecular Encoding Consortium integrates the different experiences and expertise of these leading institutions,” said Dr. Donhee Ham, the Gordon McKay Professor of Electrical Engineering and Applied Physics at Harvard University. “My research group will bring expertise in the interface of solid-state electronic chips and biological systems. I am looking forward to working with the consortium team in combining silicon integrated circuit technology with molecular biology and electrochemistry to tackle this very interesting problem.”

“DNA is the ideal way to store information for long periods of time,” said Dr. Mostafa Ronaghi, Chief Technology Officer of Illumina. “We are excited by the opportunity to collaborate with the early pioneers involved in this project and having our SBS chemistry and instruments used to decode the digital information.”

About IARPA
IARPA invests in high-risk, high-payoff research programs to tackle some of the most difficult challenges of the agencies and disciplines in the Intelligence Community. Additional information on IARPA and its research may be found on www.iarpa.gov.

About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new diagnostics, therapeutics, sustainable chemicals production, improved crops and data storage solutions. www.dnascript.co

About the Dr. Donhee Ham Research Group
Established in 2002, one of the major intellectual focuses of Donhee Ham’s research group has been on directly interfacing silicon integrated circuits with biological systems for applications in neuroscience, neurotechnology, and biomolecular spectroscopy. Notably, his group at Harvard Applied Physics in collaboration with Dr. Hongkun Park’s group at Harvard Chemistry has recently developed a silicon electronic chip with a surface nanoelectrode array that can copy the synaptic connectivity of thousands of connected mammalian neurons. http://ham.seas.harvard.edu

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact in the US for DNA Script
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com

Press contact in Europe for DNA Script
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

DNA Script Contact
publicrelations@dnascript.com

Illumina Contact
Jen Carroll
jcarroll@illumina.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release

Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release

SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release

Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 09:06:00 EET | Press release

On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the hands of children. Hayley van Loon, CEO of Crime Stoppers International, said: “It’s just a vape. It’s just a pouch. That is exactly what the criminals selling them want you to think. Nobody knows what’s in these products. They’re made in illegal factories with no safety standards and sold to anyone, including

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 09:00:00 EET | Press release

Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: "The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye